Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maytansinol is a cytotoxic macrolide and the parent alcohol of the maytansinoid family of compounds. Originally isolated from plants of the genus *Maytenus*, it acts as a potent microtubule inhibitor by binding to tubulin at the maytansine site, which is distinct from but overlaps with the vinca alkaloid binding site. This binding inhibits microtubule assembly, leading to cell cycle arrest in the G2/M phase and subsequent apoptosis. While maytansinol itself is primarily used as a reference compound in research—such as in Drosophila cancer models studied by SuviCa—its most significant clinical application is as a precursor for the synthesis of thiol-containing maytansinoids like DM1 (mertansine) and DM4. These derivatives serve as the cytotoxic payloads for various antibody-drug conjugates (ADCs), enabling the targeted delivery of highly potent tubulin inhibitors to malignant cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on maytansinol.